Audentes Therapeutics (BOLD) Misses Q1 EPS by 24c

Audentes Therapeutics (NASDAQ: BOLD) reported Q1 EPS of ($1.13), $0.24 worse than the analyst estimate of ($0.89).

For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Lululemon (LULU) PT Lowered to $115 at Freedom Broker
• StoneX on Mama’s Creations (MAMA): 'We Remain High-Conviction Buyers'